Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K
Division of Gastroenterology, McMaster University & Hamilton Health Sciences, Hamilton, ON, Canada.
Aliment Pharmacol Ther. 2003 Oct 1;18(7):705-11. doi: 10.1046/j.1365-2036.2003.01743.x.
Intravenous (IV) proton-pump inhibitor therapy is used in patients who cannot take oral medications or require greater acid suppression. Oral esomeprazole produces greater acid suppression than oral pantoprazole; however, no comparative data exist for oral esomeprazole and i.v. pantoprazole.
To compare acid suppression (time with pH>3.0, 4.0, 5.0 and 6.0) produced by standard doses of oral esomeprazole and i.v. pantoprazole in healthy subjects.
A randomized, two-way crossover study in 30 subjects receiving oral esomeprazole (40 mg o.d.) or i.v. pantoprazole (40 mg o.d.) for 5 days followed by a 2-week washout period before the second 5-day drug administration period using the crossover drug regimen.
Oral esomeprazole produced greater acid suppression than i.v. pantoprazole on day 1 [pH>3.0 (56.9%, 35.8%; P<0.001), pH>4.0 (43.4%, 25.0%; P<0.001) and pH>5.0 (28.7%, 15.6%; P<0.001)] and on day 5 [pH>3.0 (70.4%, 45.9%; P<0.001), pH>4.0 (59.2%, 33.9%; P<0.001), pH>5.0 (45.5%, 23.9%; P<0.001) and pH>6.0 (19.6%, 12.6%; P=0.045)]. The adverse event profiles indicated both treatments to be safe and well tolerated.
In healthy subjects, esomeprazole, 40 mg o.d. dispersed in water, produces greater acid suppression than pantoprazole 40 mg i.v. o.d. after 1 and 5 days of medication.
静脉注射质子泵抑制剂疗法用于无法口服药物或需要更强抑酸作用的患者。口服埃索美拉唑的抑酸作用强于口服泮托拉唑；然而，尚无口服埃索美拉唑与静脉注射泮托拉唑的对比数据。
比较标准剂量的口服埃索美拉唑和静脉注射泮托拉唑对健康受试者的抑酸作用（pH>3.0、4.0、5.0和6.0的时间）。
一项随机、双向交叉研究，30名受试者接受口服埃索美拉唑（40mg每日一次）或静脉注射泮托拉唑（40mg每日一次）治疗5天，随后经过2周的洗脱期，再使用交叉给药方案进行第二个5天的药物给药期。
在第1天，口服埃索美拉唑的抑酸作用强于静脉注射泮托拉唑[pH>3.0（56.9%，35.8%；P<0.001），pH>4.0（43.4%，25.0%；P<0.001），pH>5.0（28.7%，15.6%；P<0.001）]；在第5天，口服埃索美拉唑的抑酸作用也强于静脉注射泮托拉唑[pH>3.0（70.4%，45.9%；P<0.001），pH>4.0（59.2%，33.9%；P<0.001），pH>5.0（45.5%，23.9%；P<0.001），pH>6.0（19.6%，12.6%；P=0.045）]。不良事件情况表明两种治疗均安全且耐受性良好。
在健康受试者中，每日一次口服40mg溶于水的埃索美拉唑，用药1天和5天后的抑酸作用强于每日一次静脉注射40mg泮托拉唑。
